Our cells rely on tightly regulated signaling pathways to control when they grow, divide and survive. When these regulatory systems are disrupted, cells can acquire the ability to grow uncontrollably ...
A first-in-class nanoparticle injection sneaks antibodies into pancreatic cancer cells to clear mutant KRAS, shrinking tumors ...
Researchers at The University of Texas MD Anderson Cancer Center have identified a specific protein, RASH3D19, that is responsible for activation of RAS signaling pathways involved in aggressive tumor ...
Stories by SWNS on MSN
New blood test spots hidden traces of deadly pancreatic cancer
A highly sensitive new blood test can detect tiny traces of one of the deadliest forms of cancer – even when scans suggest ...
Northwestern Medicine scientists have demonstrated that a highly sensitive blood test can detect traces of pancreatic cancer ...
New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...
Researchers tested experimental PCAI compounds against pancreatic cancer cells and found they had powerful anticancer effects. One leading compound blocked more than 90% of cancer cell migration, ...
A new preclinical study led by researchers at The University of Texas MD Anderson Cancer Center and Weill Cornell Medicine has uncovered genetic and cell-state adaptive mechanisms that drive ...
The CodeBreaK 100 study from Amgen Inc. is a Phase 1/2 trial testing sotorasib in advanced solid tumors with a KRAS p.G12C mutation. It aims to find a safe dose, check how the drug behaves in the body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results